Logo image of IMRA

IMARA INC (IMRA) Stock Fundamental Analysis

NASDAQ:IMRA - Nasdaq - US45249V1070 - Common Stock - Currency: USD

6.32  +0.87 (+15.96%)

After market: 5.82 -0.5 (-7.91%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMRA. IMRA was compared to 193 industry peers in the Pharmaceuticals industry. While IMRA has a great health rating, there are worries on its profitability. IMRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMRA has reported negative net income.
IMRA had a negative operating cash flow in the past year.
IMRA Yearly Net Income VS EBIT VS OCF VS FCFIMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 0 -10M -20M -30M -40M -50M

1.2 Ratios

The profitability ratios for IMRA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMRA Yearly ROA, ROE, ROICIMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMRA Yearly Profit, Operating, Gross MarginsIMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021

More info and screens

8

2. Health

2.1 Basic Checks

IMRA has more shares outstanding than it did 1 year ago.
IMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMRA Yearly Shares OutstandingIMRA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
IMRA Yearly Total Debt VS Total AssetsIMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

IMRA has an Altman-Z score of 49.13. This indicates that IMRA is financially healthy and has little risk of bankruptcy at the moment.
IMRA's Altman-Z score of 49.13 is amongst the best of the industry. IMRA outperforms 96.86% of its industry peers.
IMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 49.13
ROIC/WACCN/A
WACCN/A
IMRA Yearly LT Debt VS Equity VS FCFIMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 32.51 indicates that IMRA has no problem at all paying its short term obligations.
IMRA has a better Current ratio (32.51) than 97.31% of its industry peers.
IMRA has a Quick Ratio of 32.51. This indicates that IMRA is financially healthy and has no problem in meeting its short term obligations.
IMRA's Quick ratio of 32.51 is amongst the best of the industry. IMRA outperforms 97.31% of its industry peers.
Industry RankSector Rank
Current Ratio 32.51
Quick Ratio 32.51
IMRA Yearly Current Assets VS Current LiabilitesIMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.63% over the past year.
EPS 1Y (TTM)29.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IMRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.07% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.88%
EPS Next 2Y33.2%
EPS Next 3Y21.07%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMRA Yearly Revenue VS EstimatesIMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024
IMRA Yearly EPS VS EstimatesIMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMRA Price Earnings VS Forward Price EarningsIMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMRA Per share dataIMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

IMRA's earnings are expected to grow with 21.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.2%
EPS Next 3Y21.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMARA INC

NASDAQ:IMRA (2/23/2023, 8:00:02 PM)

After market: 5.82 -0.5 (-7.91%)

6.32

+0.87 (+15.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-25 2022-10-25
Earnings (Next)03-13 2023-03-13
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners21.12%
Ins Owner Change0%
Market Cap165.80M
Analysts43.33
Price Target1.43 (-77.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.58%
Min EPS beat(2)15.75%
Max EPS beat(2)29.41%
EPS beat(4)4
Avg EPS beat(4)20.25%
Min EPS beat(4)5.01%
Max EPS beat(4)30.81%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)2.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.89
P/tB 2.89
EV/EBITDA N/A
EPS(TTM)-1.71
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.76
OCFYN/A
SpS0
BVpS2.18
TBVpS2.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.99%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.51
Quick Ratio 32.51
Altman-Z 49.13
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)166.26%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.27%
EPS Next Y38.88%
EPS Next 2Y33.2%
EPS Next 3Y21.07%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.98%
EBIT Next 3Y20.6%
EBIT Next 5YN/A
FCF growth 1Y-25.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.06%
OCF growth 3YN/A
OCF growth 5YN/A